| Course | HCR 579 Translational Research in Drug Discovery and Development |
|---|---|
| Module | Module 4 |
| Paper type | Phase 0 study analysis |
| Length | About 619 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 579 Module 4
One Dose, Two Biopsies: Dissecting the First Oncology Phase 0 Trial
Student Name
MS in Regulatory Science, Arizona State University
HCR 579: Translational Research in Drug Discovery and Development
Instructor Name
Month Day, Year
One Dose, Two Biopsies: Dissecting the First Oncology Phase 0 Trial
What a Phase 0 Trial Is
A Phase 0 trial gives a very small number of people a single dose, or a few low doses, of an investigational drug, well below the level expected to have therapeutic effect. Its purpose is not to treat or to find the maximum tolerated dose but, as the course text puts it in describing early translational studies, to answer early questions (Shah & Wells, 2020): does the drug reach its target in humans, does it act on the target and how is it absorbed and cleared? FDA's 2006 guidance on exploratory IND studies allowed these trials with reduced nonclinical requirements, because exposure is limited. Supporters argue that Phase 0 trials can stop failing drugs early and speed promising ones, in a development system where fewer than one in ten new molecules entering Phase 1 reach the market (Marchetti & Schellens, 2007).
The Study
Kummar et al. (2009) gave 13 patients with advanced cancers a single oral dose of ABT-888 at 10, 25 or 50 mg. The drug inhibits poly(ADP-ribose) polymerase, an enzyme that helps cancer cells repair DNA. Blood and tumor biopsies were collected before and after the dose to measure the enzyme's product, poly(ADP-ribose), in tumor tissue and in blood cells, along with drug levels over time. Nine patients had paired tumor biopsies.
Design Features
| Feature | Choice in this trial | Why it fits Phase 0 |
|---|---|---|
| Dose | Single dose, 10 to 50 mg | Limits exposure; aims to show target effect, not tumor response |
| Participants | 13 adults with advanced cancer | Small number enough for a pharmacodynamic question |
| Primary endpoint | Change in PAR levels in tumor and blood | Direct proof of target modulation |
| Statistics | A new method for small pharmacodynamic samples | Standard designs need far larger samples |
| Nonclinical package | Reduced, under exploratory IND guidance | Low exposure lowers toxicology needs |
What It Achieved
The drug was well absorbed and well tolerated, and the 25-mg and 50-mg doses produced statistically significant inhibition of poly(ADP-ribose) in both tumor biopsies and blood cells. Within five months of activation, the trial had produced pharmacokinetic and biochemical data that shaped the dose and schedule of later Phase 1 combination trials (Kummar et al., 2009). That speed is the strongest case for Phase 0 designs: the team learned in months whether the drug hit its target in people, information that would otherwise have come later and at higher doses.
Limitations
Thirteen patients and a single dose cannot reveal safety at therapeutic doses or efficacy. Tumor biopsies vary in quality and timing, so a negative result could reflect sampling rather than drug action. And the approach suits drugs with a measurable target effect; drugs without a validated pharmacodynamic marker gain less from it.
Ethical Concerns
No Prospect of Benefit
Phase 0 participants receive a dose too low to treat their cancer. Consent must state this plainly, because patients with advanced disease may hope any trial could help them, a form of the therapeutic misconception.
Research Biopsies
Tumor biopsies taken only for research carry pain and risk of bleeding or infection. The risk is justified only if the scientific value is high and the biopsy procedure is as safe as possible, with clear stopping rules.
Delaying Other Treatment
Participation must not delay access to therapeutic trials or standard care. Short Phase 0 timelines help, but the protocol should say so.
Conclusion
The ABT-888 Phase 0 trial showed what the design can do: answer a precise translational question quickly with few patients. Its limits, small size and no therapeutic intent, are built into the design, and its central ethical demand is honest consent about the lack of benefit and the burden of research biopsies.
References
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., Murgo, A. J., Collins, J., Steinberg, S. M., Eliopoulos, H., Giranda, V. L., Gordon, G., Helman, L., Wiltrout, R., Tomaszewski, J. E., . . . Doroshow, J. H. (2009). Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. Journal of Clinical Oncology, 27(16), 2705-2711. https://doi.org/10.1200/JCO.2008.19.7681
Marchetti, S., & Schellens, J. H. M. (2007). The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. British Journal of Cancer, 97(5), 577-581. https://doi.org/10.1038/sj.bjc.6603925
Shah, K. P., & Wells, C. E. (2020). Translational research in drug discovery and development: A Top Hat interactive text. Top Hat Monocle.
Reading the HCR 579 Module 4 assignment instructions
Written Assignment 3, worth 75 points, falls in Module 4 of HCR 579, which covers ethical concerns in translational research. The syllabus includes a Phase 0 dissection in its list of papers and leaves the detailed instructions to Canvas. Dissecting a study means taking it apart piece by piece: its purpose, design, participants, dose, endpoints, statistics, results and limitations, and, given the module, the ethical issues it raises. Phase 0 trials are a good test of translational thinking because they exist to answer early questions about whether a drug reaches and affects its target in people, with doses too small to help the participants. Choose a published Phase 0 trial with a full report, ideally one conducted under FDA's exploratory IND guidance, so you can explain how its reduced nonclinical package and small size fit its purpose.
How the HCR 579 Module 4 example is put together
The sample begins by explaining what Phase 0 trials are for and why they were introduced, citing a source on development attrition. It then describes the study, a single-dose trial with paired biopsies, and lays out its design features in a table that explains why each fits a Phase 0 purpose. Results are reported with what they made possible for later trials. A limitations section follows, and the ethics section, matched to the module, discusses lack of benefit, research biopsies and delay of other treatment under separate headings. The conclusion ties the design's strengths and limits to its ethical demands. The ethics section stays specific to this trial rather than restating general principles.
HCR 579 Module 4 rubric: what earns full marks
Seventy-five points ride on the Phase 0 dissection. A strong dissection explains Phase 0 trials accurately, describes every element of the chosen study's design and connects each to its purpose, reports results correctly, names real limitations and analyzes the ethical issues specific to Phase 0 research. Points are lost when the paper treats a Phase 0 trial like a Phase 1 trial, when design elements are listed without explanation, when the ethics section is generic and when results are overstated, such as implying the drug was shown to work against cancer. Readers value attention to consent and research biopsies, since those are the core ethical questions the module raises.
HCR 579 Module 4 help with common mistakes
Choose a Phase 0 study with a full published report. Explain the purpose of Phase 0 before you describe the study. Use a table to connect design features to purpose. Report the pharmacodynamic endpoint precisely. Do not claim efficacy. Discuss the lack of benefit and any research biopsies as ethical issues. Note what the study made possible next. If you have trouble finding a Phase 0 trial, the desk can suggest published examples. Report the statistical approach in plain words, since Phase 0 designs often use unusual methods for small samples. Explain what the trial made possible for later studies, which is the main argument for its existence.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 579 and MS in Regulatory Science sample papers
- HCR 579 Module 2: Written Assignment 1: Evaluating a Translational Study
- HCR 579 Module 3: Written Assignment 2: Analysis of an IACUC Application
- HCR 579 Module 5: Annotated Bibliography: Patient-Derived Organoids
- HCR 579 Module 6: Assignment 4: Presenting a Precision Medicine Protocol
- HCR 579 Module 7: Ethical Paper: Precision Medicine
- HCR 576 Module 7: Paper: Comparing the U.S. and EU Regulatory Frameworks
- HCR 543 Module 7: Summative Evaluation Paper: Emerging Food Safety Issues
- HCR 555 Module 5: Assignment 4: Globalization, Off-Label Use, Biologics and Counterfeits
- HCR 563 Module 3: Assignment 1: Global Device Registration Slides (Japan)
HCR 579 Module 4 questions, answered
Where can I find a free HCR 579 Module 4 sample paper?
This page holds the complete Written Assignment 3, dissecting the first oncology Phase 0 trial of a PARP inhibitor.
What is a Phase 0 trial?
A very small, early human study with one or a few low doses, designed to show whether a drug reaches and affects its target.
Do Phase 0 participants benefit from the drug?
No. Doses are too low to be therapeutic, which consent must state clearly.
What did the ABT-888 Phase 0 trial show?
Doses of 25 and 50 mg significantly inhibited the target enzyme's activity in tumors and blood cells within five months of starting.
What ethical issues do Phase 0 trials raise?
No prospect of benefit, research-only biopsies and the risk of delaying other treatment.